Clinical Trial Update: Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated the combination of gemcitabine, docetaxel, and bevacizumab in selected sarcoma subtypes, including leiomyosarcoma and angiosarcoma, wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angiosarcoma
• Leiomyosarcoma
• Sarcoma
• Undifferentiated Pleomorphic Sarcoma

Drugs mentioned

• Avastin (bevacizumab)
• Gemzar (gemcitabine)
• Taxotere (docetaxel)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Sarcoma, Leiomyosarcoma | Phase 2 | Status: COMPLETED | Results posted: 2016-01-25